RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2010; 135(37): 1819-1822
DOI: 10.1055/s-0030-1247869
DOI: 10.1055/s-0030-1247869
Arzneimittel & Pharmakotherapie | Review article
Onkologie© Georg Thieme Verlag KG Stuttgart · New York
Sorafenib
SorafenibWeitere Informationen
Publikationsverlauf
eingereicht: 12.4.2010
akzeptiert: 22.7.2010
Publikationsdatum:
20. August 2010 (online)

Schlüsselwörter
Sorafenib - Tyrosin-Kinase-Inhibitor
Keywords
sorafenib - tyrosine kinase inhibitor
Literatur
- 1
Cheng A L, Kang Y K, Chen Z, Tsao C J, Qin S, Kim J S. et
al .
Efficacy and safety of sorafenib in patients in
the Asia-Pacific region with advanced hepatocellular carcinoma:
a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol.
2009;
10
25-34
MissingFormLabel
- 2
Escudier B, Eisen T, Stadler W M, Szczylik C, Oudard S, Siebels M. et al, TARGET Study Group .
Sorafenib in advanced clear-cell renal-cell carcinoma.
N
Engl J Med.
2007;
356
125-134
MissingFormLabel
- 3
Escudier B, Eisen T, Stadler W M, Szczylik C, Oudard S, Staehler M. et al .
Sorafenib
for treatment of renal cell carcinoma: Final efficacy and safety
results of the phase III treatment approaches in renal cancer global
evaluation trial.
J Clin Oncol.
2009;
27
3312-3318
MissingFormLabel
- 4
Escudier B, Szczylik C, Hutson T E, Demkow T, Staehler M, Rolland F. et al .
Randomized
phase II trial of first-line treatment with sorafenib versus interferon
Alfa-2a in patients with metastatic renal cell carcinoma.
J
Clin Oncol.
2009;
27
1280-1289
MissingFormLabel
- 5 Fachinformation Sorafenib. Stand Juni 2009
MissingFormLabel
- 6
Force T, Krause D S, Van Etten R A.
Molecular mechanisms of cardiotoxicity of
tyrosine kinase inhibition.
Nat Rev Cancer.
2007;
7
332-344
MissingFormLabel
- 7
Hauschild A, Agarwala S S, Trefzer U, Hogg D, Robert C, Hersey P. et al .
Results of
a phase III, randomized, placebo-controlled study of sorafenib in
combination with carboplatin and paclitaxel as second-line treatment
in patients with unresectable stage III or stage IV melanoma.
J Clin Oncol.
2009;
27
2823-2830
MissingFormLabel
- 8
Llovet J M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J F, SHARP I nvestigators
Study Group. et al .
Sorafenib in advanced
hepatocellular carcinoma.
N Engl J Med.
2008;
359
378-390
MissingFormLabel
- 9
May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O. et al .
Transgenic system for conditional induction
and rescue of chronic myocardial hibernation provides insights into
genomic programs of hibernation.
Proc Natl Acad Sci U
S A.
2008;
105
282-287
MissingFormLabel
- 10
McDermott D F, Sosman J A, Gonzalez R, Hodi F S, Linette G P, Richards J. et al .
Double-blind randomized phase II study of the combination of sorafenib
and dacarbazine in patients with advanced melanoma: a report from
the 11 715 Study Group.
J Clin Oncol.
2008;
26
2178-2185
MissingFormLabel
- 11
Therasse P, Arbuck S G, Eisenhauer E A, Wanders J, Kaplan R S, Rubinstein L. et
al .
New guidelines to evaluate the response to treatment
in solid tumors. European Organization for Research and Treatment
of Cancer, National Cancer Institute of the United States, National
Cancer Institute of Canada.
J Natl Cancer Inst.
2000;
92
205-216
MissingFormLabel
- 12
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R A. et al .
Discovery
and development of sorafenib: a multikinase inhibitor for treating
cancer.
Nat Rev Drug Discov.
2006;
5
835-844
MissingFormLabel
- 13
Wilhelm S M, Carter C, Tang L, Wilkie D, McNabola A, Rong H. et al .
BAY 43 – 9006
exhibits broad spectrum oral antitumor activity and targets the
RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis.
Cancer
Res.
2004;
64
7099-7109
MissingFormLabel
Prof. Dr. Thomas Eschenhagen
Institut für Experimentelle und Klinische
Pharmakologie und Toxikologie
Universitätsklinikum Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg
Telefon: 040/74105 2180
Fax: 040/74105
4876
eMail: t.eschenhagen@uke.uni-hamburg.de